<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000836</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 294</org_study_id>
    <nct_id>NCT00000836</nct_id>
  </id_info>
  <brief_title>A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT)</brief_title>
  <official_title>A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To compare the safety and efficacy of sevirumab (MSL 109; Protovir), human&#xD;
      anti-cytomegalovirus (CMV) monoclonal antibody, plus active primary treatment versus placebo&#xD;
      plus active primary treatment in AIDS patients with newly diagnosed and relapsed CMV&#xD;
      retinitis.&#xD;
&#xD;
      Ganciclovir and foscarnet are used for treatment of CMV retinitis, but cause hematologic&#xD;
      toxicity and nephrotoxicity, respectively. Despite continued maintenance therapy with these&#xD;
      drugs, relapse occurs in 85 percent of patients within 4 months. Studies suggest that MSL&#xD;
      109, a human monoclonal antibody, when given with either ganciclovir or foscarnet, may&#xD;
      increase initial response and prolong time to progression in patients with CMV retinitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ganciclovir and foscarnet are used for treatment of CMV retinitis, but cause hematologic&#xD;
      toxicity and nephrotoxicity, respectively. Despite continued maintenance therapy with these&#xD;
      drugs, relapse occurs in 85 percent of patients within 4 months. Studies suggest that MSL&#xD;
      109, a human monoclonal antibody, when given with either ganciclovir or foscarnet, may&#xD;
      increase initial response and prolong time to progression in patients with CMV retinitis.&#xD;
&#xD;
      Patients are randomized to receive either MSL 109 or placebo every 2 weeks as supplemental&#xD;
      therapy to primary CMV treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">August 1998</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>300</enrollment>
  <condition>Cytomegalovirus Retinitis</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevirumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication: Required:&#xD;
&#xD;
          -  Primary CMV treatment.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  AIDS.&#xD;
&#xD;
          -  Active CMV retinitis.&#xD;
&#xD;
          -  At least one photographable lesion of one-quarter or more optic disc area in size.&#xD;
&#xD;
          -  Undergoing primary treatment for CMV retinitis that is not contraindicated with MSL&#xD;
             109.&#xD;
&#xD;
          -  Visual acuity in at least one eye of 3 or more letters on Early Treatment Diabetic&#xD;
             Retinopathy Study ( ETDRS ) chart at 1 meter distance ( Snellen equivalent 5/200 ).&#xD;
             Note:&#xD;
&#xD;
          -  Exceptions may be made if visual acuity impairment is possibly reversible and there is&#xD;
             at least light perception in that eye.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Retinal detachment not scheduled for surgical repair.&#xD;
&#xD;
          -  Media opacity that precludes visualization of the fundus.&#xD;
&#xD;
          -  Active medical problems sufficient to hinder study compliance.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  IVIG.&#xD;
&#xD;
          -  CMV immune globulin ( CMVIG ).&#xD;
&#xD;
          -  Interferon alpha.&#xD;
&#xD;
          -  Interferon gamma.&#xD;
&#xD;
          -  Interleukin-2 ( IL-2 ).&#xD;
&#xD;
        Drug or alcohol abuse sufficient to hinder study compliance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCSD - Shiley Eye Ctr / SOCA</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>920930946</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA - Jules Stein Eye Institute / SOCA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>900957003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF - San Francisco Gen Hosp</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Univ / SOCA</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hosp / SOCA</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>212879217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Univ Med Ctr / SOCA</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 24, 2012</last_update_submitted>
  <last_update_submitted_qc>October 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2012</last_update_posted>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Antibodies, Monoclonal</keyword>
  <keyword>Cytomegalovirus Retinitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytomegalovirus Retinitis</mesh_term>
    <mesh_term>Retinitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

